Watching Claude think silently
-
Nº LII
- Date
- 08 Jul 2026
- Issue
- 52
- Stories
- Six
- Editor
- ARC
Anthropic cracks open Claude's inner monologue while a cancer copilot and a metabolic-engineering foundation model quietly reset their fields.
Anthropic maps Claude's silent thoughts
Anthropic published interpretability research showing Claude runs reasoning steps its output never mentions — noticing bugs, identifying images, planning ahead — inside what the team calls the J-space (named for the Jacobian, the calculus tool used to isolate the signal). The J-space sits in raw neural activations, distinct from chain-of-thought text that models can fabricate or hide. Anchors a new reference method for auditing what a model actually did versus what it said it did, which lands directly on biology deployments where hidden reasoning inside a clinical or lab agent is a regulatory problem, not a curiosity.
Also discussed on X.
Oncology copilot goes model-agnostic
Large Cancer Assistant orchestrates clinical decision support across swappable base models, letting hospitals route oncology queries through whichever LLM meets their compliance posture that quarter. Moves clinical AI from single-vendor lock-in toward orchestration layers, where the model becomes a replaceable component rather than the product — a structural shift oncology IT has been waiting on.
Foundation model for metabolic engineering
Canopy trains a heterograph foundation model (one that learns from graphs mixing different node types — genes, metabolites, reactions — in a single representation) for metabolic engineering. Establishes a general-purpose pretrained backbone for pathway design, which until now has lived on bespoke per-project models — a fragmentation we noted when evaluating what LLMs can and can't do with metabolic models; strain engineering gets the transferable-representation era genomics got five years ago.
BGC sequence predicts natural-product traits
A foundation model predicts natural product properties, bioactivity, and structural similarity directly from biosynthetic gene cluster sequence. Collapses the sequence-to-product gap that has kept natural-product discovery dependent on expression screens, shifting the cost ceiling for prioritizing which clusters to actually clone.
Warning on big-lab AI agents
An HN post warns AI researchers against feeding proprietary work into agents from major labs, citing unclear retention and training-data policies. Raises the debate on IP hygiene as a vendor-selection criterion for any group doing frontier method work — biology teams building novel agent scaffolds are squarely in scope.
AI designs peptides with reduced alphabets
Peptide designer targets custom secondary-structure motifs while restricting the amino acid alphabet, a constraint that matters for manufacturability and immunogenicity. Narrows the gap between generative peptide design and what CMC teams can actually synthesize at scale.
Reply with your discoveries. A human reads them. Forward freely.
|